跳至主要内容
临床试验/TCTR20210409003
TCTR20210409003招募中3 期

Randomized-controlled trial evaluating the outcome between switching to tenofovir disoproxil fumarate(TDF)/lamivudine(3TC)/dolutegravir(DTG) versus maintaining the current NNRTI or boosted-PI -containing regimen in non-virologic failure HIV infection in Thailand

Atlanta Medicare0 个研究点目标入组 64 人开始时间: 2021年4月9日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
64

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1. Thai adult age > 18 year-old
  • 2. Positive HIV-1 antibody or plasma HIV-1 viral load
  • 3. Currently treated with 2NRTI/1NNRTI or boosted-PIs
  • 4. Willing to participate throughout 48 weeks period and have a regular follow-up at Suddhavej hospital

排除标准

  • 1. Women with childbearing age who wish to be pregnant in the next 52 weeks period
  • 2. Women with childbearing age who deny contraception
  • 3. Pregnant women
  • 4. Documented HIV resistance
  • 5. History of DTG hypersensitivity or the following substances: D-Mannitol, Microcystalline Cellulose, Povidone, Croscarmellose Sodium, Sodium Stearyl Fumarate, Talc, white film coat
  • 6. Virologic failure
  • 7. Creatinine clearance (CKD-EPI Asia) < 60 ml/min
  • 8. Cirrhosis child B-C
  • 9. Alanine aminotransferase (ALT) >= 5X of upper limit or ALT >= 3X +total bilirubin >= 1.5X of upper limit
  • 10. Currently treated tuberculosis
  • 11. Currently on >= 1000 mg of metformin

研究者

发起方
Atlanta Medicare

相似试验